T1	HMM 981 1013	from baseline to week 18 in 6MWD
T2	HMM 1101 1130	week 18, WHO functional class
T3	HMM 1273 1285	respectively
T4	HMM 1369 1383	(P = 0.090).
T5	HMM 1384 1398	Adverse events
T6	HMM 1455 1539	100 mg) included headache, peripheral edema, dizziness, nausea, extremity pain, and
T7	HMM 1616 1653	100 mg improved functional class but
